Observational study of Canadian cancer patients with rare molecular alterations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects data on Canadian cancer patients who have rare genetic changes in their tumors, which may respond to specific cancer therapies. It aims to create a cohort to understand the natural history of these cancers and compare treatment outcomes, including effectiveness and side effects, across different therapies. The study will also investigate the incidence and outcomes of specific patterns of cancer spread, such as brain metastases, and analyze real-world treatment patterns over time. By focusing on molecularly subtyped tumors, the study seeks to optimize treatment responses and improve patient survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 18 years at cancer diagnosis
* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
* Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy)
* Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment

Exclusion Criteria:

* Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent

Where it's running

• Tom Baker Cancer Centre - University of Calgary - Alberta Health Services
  Calgary, Alberta, Canada Recruiting
• BC Cancer
  Vancouver, British Columbia, Canada Recruiting
• CancerCare Manitoba/University of Manitoba
  Winnipeg, Manitoba, Canada Recruiting
• Dr. Everett Chalmers Regional Hospital
  Fredericton, New Brunswick, Canada Recruiting
• Queen Elizabeth II (QEII) Health Sciences Centre
  Halifax, Nova Scotia, Canada Recruiting
• William Osler Health System - Brampton Civic Hospital
  Brampton, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Geoffrey Liu, MD, MSc — Princess Margaret Cancer Centre
• Study coordinator: Faisal Al-Agha, BSc
• Email: faisal.al-agha@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

• Wearable ECG patch monitoring for people receiving end-of-life cancer care

  This tests whether a small wearable ECG patch can remotely track vital signs for people with advanced cancer in hospice to help spot infections, relate symptoms to physiology, and improve estimates of how long someone may have to live.

  Recruiting Our Lady's Hospice and Care Services · Dublin · NCT07512505

• Photo-based exploration of hope in young people receiving phase 1/2 cancer therapy

  This project will try to understand how young people (ages 12–25) and their caregivers experience and adapt their hope while they are enrolled in phase 1 or 2 cancer therapy using photos and interviews.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07444216

• FH-006 injection study for advanced solid tumors

  This study tests FH-006, alone and with SHR-1316 and paclitaxel, to see if it is safe and tolerable in adults with unresectable or metastatic solid tumors who have measurable disease.

  Recruiting at 2 sites Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07136142

• How probiotics affect survival, treatment response, and gut microbiota during cancer therapy

  This test will see if taking a probiotic supplement during cancer treatment helps adults with cancer live longer, respond better to therapy, or have healthier gut bacteria.

  Recruiting Chang Gung Memorial Hospital · New Taipei City · NCT06998823

• IntraTumor T-Cell Boost with Dual Immune Checkpoint Inhibitors in ARID1A-Mutated Esophageal/Gastric Adenocarcinoma

  A first-in-human test of a single-dose combination of tremelimumab and durvalumab in adults with ARID1A-mutated, non-metastatic esophageal, GEJ, or stomach adenocarcinoma to see if it can increase tumor T cells.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT06824363

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.